|
コンドウ シュンスケ
KONDOU Shunsuke
近藤 俊輔 所属 医学部 医学科（東京女子医科大学病院） 職種 教授 |
|
| 論文種別 | 総説 |
| 言語種別 | 英語 |
| 査読の有無 | 査読あり |
| 招待の有無 | 招待あり |
| 表題 | Expanding indications and developmental landscape of HER2-targeted therapies in breast cancer: a pharmacotherapeutic perspective. |
| 掲載誌名 | 正式名：Expert opinion on pharmacotherapy 略 称：Expert Opin Pharmacother ISSNコード：17447666/14656566 |
| 掲載区分 | 国外 |
| 巻・号・頁 | pp.2025 Nov 16 |
| 著者・共著者 | Hikari Sano, Hideyuki Hayashi, Naomi Nakao, Hiroko Hosoi, Shunsuke Kondo |
| 担当区分 | 筆頭著者 |
| 発行年月 | 2025/11 |
| 概要 | INTRODUCTION:This review provides an updated overview of the evolving pharmacologic landscape of human epidermal growth factor receptor 2 (HER2)-targeted therapies in breast cancer, highlighting key clinical trial data, recent indication expansions, resistance mechanisms, and emerging therapeutic agents in development.AREAS COVERED:This review draws on a comprehensive literature search of published studies and major oncology conference proceedings, focusing primarily on data from key phase III clinical trials of HER2-targeted therapies. Studies published within the past decade that have influenced current standards of care were prioritized.EXPERT OPINION:The treatment paradigm for HER2-expressing breast cancer is evolving rapidly. Trastuzumab deruxtecan has redefined management for both HER2-positive and the newly recognized HER2-low subgroups, while tucatinib offers a critical systemic option for central nervous system metastases. Optimal sequencing and resistance management remain critical challenges in this dynamic field. Nonetheless, HER2-targeted pharmacotherapy continues to advance rapidly, driven by innovative drug designs and strategic clinical developments. |
| DOI | 10.1080/14656566.2025.2591813 |
| PMID | 41243354 |